lapatinib has been researched along with cblc137 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (cblc137) | Trials (cblc137) | Recent Studies (post-2010) (cblc137) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 39 | 0 | 39 |
| Protein | Taxonomy | lapatinib (IC50) | cblc137 (IC50) |
|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 3A | Mus musculus (house mouse) | 7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dermawan, JK; Gurova, KV; Hitomi, M; Lathia, JD; Purmal, AA; Rich, JN; Sandlesh, P; Silver, DJ; Sloan, AE; Stark, GR; Venere, M; Wu, Q | 1 |
1 other study(ies) available for lapatinib and cblc137
| Article | Year |
|---|---|
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
Topics: Animals; Brain Neoplasms; Carbazoles; DNA-Binding Proteins; Glioblastoma; High Mobility Group Proteins; Humans; Lapatinib; Mice; Quinazolines; Transcriptional Elongation Factors | 2016 |